Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study
April 10, 2024 12:04 ET
|
Raydiant Oximetry
The FDA has approved the Investigational Device Exemption (IDE) of Lumerah for an Early Feasibility Study (EFS) of pregnant women during labor and delivery
FDA Clears RedDrop Dx, Inc.’s Blood Collection Device, RedDrop One
March 22, 2024 10:59 ET
|
Innosphere Ventures
Fort Collins, CO, March 22, 2024 (GLOBE NEWSWIRE) -- RedDrop Dx, Inc., Innosphere Ventures Client Company, is pleased to announce that its innovative blood collection device, RedDrop One, has...
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
February 16, 2024 11:24 ET
|
F. Hoffmann-La Roche Ltd
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate...
La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)
January 16, 2024 13:30 ET
|
Hyloris Pharmaceuticals SA
La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA) Le PTX-252 (précédemment appelé agent plécoïdeTM) est une nouvelle...
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)
January 16, 2024 13:30 ET
|
Hyloris Pharmaceuticals SA
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity developed in...
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
December 26, 2023 16:01 ET
|
Coherus BioSciences, Inc.
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023 17:11 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
December 13, 2023 07:25 ET
|
Arch Biopartners
TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to...
Hyloris annonce l'approbation du Gel Podofilox par la FDA américaine
December 04, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris annonce l'approbation du Gel Podofilox par la FDA américaine - Produit référencé comme HY-016, ciblant les condylomes génitaux et périanaux - Lancement de la commercialisation aux États-Unis...
Hyloris announces US FDA approval for Podofilox Gel
December 04, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
Hyloris announces US FDA approval for Podofilox Gel Product previously referenced as HY-016, targeting genital and perianal wartsUS Commercialization by partner Padagis to start in December...